ReviewJournal of neurovirology2001
A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region.
Review in Journal of neurovirology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 109 citations in OpenAlex.
- Asymptomatic reactivation of JC virus in patients treated with natalizumab.The New England journal of medicine · 2009Trial
- Review
- Molecular characterization of JC virus in progressive multifocal leukoencephalopathy cases from India.Scientific reports · 2025Article
- Successful Recovery from Meningoencephalitis Associated with Archetype-like JC Virus in a Lung Transplant Recipient: Case Report and Review of the Literature.Annals of clinical case reports · 2025Article
- Article
- Rearrangement in the Hypervariable Region of JC Polyomavirus Genomes Isolated from Patient Samples and Impact on Transcription Factor-Binding Sites and Disease Outcomes.International journal of molecular sciences · 2022Article
- Viral Genomic Characterization and Replication Pattern of Human Polyomaviruses in Kidney Transplant Recipients.Viruses · 2020Observational
- Review
- Human Polyomaviruses in the Cerebrospinal Fluid of Neurological Patients.Microorganisms · 2019Article
- Progressive multifocal leukoencephalopathy in Zambia is caused by JC virus with prototype regulatory region.Journal of neurovirology · 2019Article
- Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Frontiers in immunology · 2018Review
- Exploring the role of NCCR variation on JC polyomavirus expression from dual reporter minicircles.PloS one · 2018Article
- Article
- Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission.World journal of virology · 2016Article
- Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.Frontiers in microbiology · 2016Article
- JC virus nucleotides 376-396 are critical for VP1 capsid protein expression.Journal of neurovirology · 2015Article
- Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.Journal of neurovirology · 2015Article
- JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.Journal of virology · 2015Article
- An animal model for progressive multifocal leukoencephalopathy.The Journal of clinical investigation · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The human polyomavirus JCV is responsible for the central nervous system (CNS) demyelination observed in cases of progressive multifocal leukoencephalopathy (PML). Lytic infection of oligodendrocytes, the cells that constitute the basis of myelin in the CNS, is established by JCV in conjunction with immunosuppressive conditions. Beyond this, however, many questions related to JCV pathogenesis remain unanswered. The JCV regulatory region is a hypervariable noncoding sequence positioned between the early and late protein-coding regions. The particular nucleotide sequence of a JCV regulatory region affects levels of viral transcription and replication. Modifications to this promoter/enhancer structure can alter the cellular host range and may be responsible for switching JCV between states of lytic and latent infection. The regulatory region structure has, therefore, been used to distinguish JCV variants. Nucleotide sequencing studies have uncovered numerous variations of regulatory region structure. Until now, however, no inclusive nomenclature existed that linked variants by regulatory region structure and/or activity. We have arranged all known variant JCV regulatory regions into quadrants according to the integration of particular sequence sections and repetition of sequence section groups. This arrangement of regulatory regions results in an updated nomenclature that is well-suited for describing the relationships between JCV variants. Four distinct structural forms (I-S, I-R, II-S, and II-R) are defined along with tissue tropisms. This design provides logical connections between the variant regulatory regions and may be useful for elucidating crucial steps in JCV pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.